<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391390</url>
  </required_header>
  <id_info>
    <org_study_id>BJ-7072035</org_study_id>
    <nct_id>NCT01391390</nct_id>
  </id_info>
  <brief_title>Melatonin Treatment for Tardive Dyskinesia in Schizophrenia</brief_title>
  <official_title>The Effect of Melatonin Treatment on Tardive Dyskinesia and Oxidative Stress: A Double-Blind Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing HuiLongGuan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing HuiLongGuan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on
      therapy to antipsychotics will be performed to examine the effects of melatonin on tardive
      dyskinesia symptoms and cognitive deficits in 120 patients with established tardive
      dyskinesia (TD). This study addresses a free radical hypothesis of TD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Since it has been proposed that neuroleptic-induced increases in free-radical production
           may relate to the development of TD, the investigators hypothesize that melatonin, an
           effective antioxidant, may attenuate the severity of tardive dyskinesia symptoms.

        2. Due to increased cognitive deficits in patients with TD and implication of oxidative
           stress in cognitive impairment, the investigators hypothesize that both cognitive
           impairment and tardive dyskinesia symptoms may be induced by the same pathophysiological
           stimulus--oxidative stress. Hence, the investigators further hypothesize that both
           tardive dyskinesia symptoms and cognitive deficits in patients with TD may be improved
           by melatonin simultaneously.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Simpson-Angus Scale for extrapyramidal side effects (SAS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Tardive Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Melatonin, antioxidant, oxidative stress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin is an active treatment for TD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo look like the active drug, and same dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>10mg/day, 12-week treatment</description>
    <arm_group_label>Melatonin, antioxidant, oxidative stress</arm_group_label>
    <other_name>APRD00742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10mg/day, 12-week treatment for TD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of both schizophrenia and TD;

          2. duration of TD symptoms longer than 1 year;

          3. on stable doses of antipsychotic drug for at least 6 months;

          4. between 18 and 70 years of age.

        Exclusion Criteria:

          1. comorbid neurological illness other than TD;

          2. if they have received vitamin C or vitamin E within 1 month before the start of the
             study;

          3. alcohol/drug abuse;

          4. acute, unstable medical condition;

          5. pregnant or breastfeeding female;

          6. use of other antioxidants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lian Y Cao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing HuiLongGuan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing HuiLongGuan hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 10, 2016</last_update_submitted>
  <last_update_submitted_qc>July 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing HuiLongGuan Hospital</investigator_affiliation>
    <investigator_full_name>Xiang Yang Zhang</investigator_full_name>
    <investigator_title>Director, Biological Psychiatry Center</investigator_title>
  </responsible_party>
  <keyword>Tardive Dyskinesia</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

